Results 31 to 40 of about 1,694,367 (292)

Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024) [PDF]

Exploration of Drug Science
Since our previous summary of the 74 FDA-approved kinase inhibitors in clinical and preclinical trials for non-cancerous neurological treatment, the US FDA has approved 13 additional kinase inhibitors since early 2022.
Hassan Aliashrafzadeh, Dewey Liu, Samantha De Alba, Imad Akbar, Austin Lui, Jordan Vanleuven, Ryan Martin, Zhang Wang, Da Zhi Liu   +8 more
doaj   +1 more source

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [PDF]

, 2013
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase ...
Oliver G Ottmann, Martin Ruthardt, Oliver G. Ottmann, Oliver G. Ottmann (485229), Falkenburg, J.H.F., Marcus Liebermann (485228), Bart A. Nijmeijer (485227), Pfeifer, Heike, Falkenburg, J. H. Frederik, J. H. Frederik Falkenburg, Ruthardt, Martin, Tamara Tesanovic, Tesanovic, Tamara, Bart A Nijmeijer, Heike Pfeifer, Ottmann, Oliver G., Susanne Badura (485223), Sylvia Wystub, Sylvia Wystub (485226), Liebermann, M., Marcus Liebermann, Bart A. Nijmeijer, Ottmann, O.G., Nijmeijer, Bart A., Badura, S., Susanne Badura, Wystub, Sylvia, Pfeifer, H., J H Frederik Falkenburg, Tamara Tesanovic (485224), Martin Ruthardt (66634), Wystub, S., Nijmeijer, B.A., Ruthardt, M., Tesanovic, T., Badura, Susanne, Heike Pfeifer (485225), J. H. Frederik Falkenburg (210432), Liebermann, Marcus   +38 more
core   +1 more source

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients

Pakistan Armed Forces Medical Journal, 2022
Objective: To look for QTc changes associated with Tyrosine Kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: Comparative cross-sectional study.
Rahimullah Khattak, Riaz Ahmad, Muhammad Nadeem, Huma Amjad, Amjad Khan, Ibtisam .   +5 more
doaj   +1 more source

Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting

eLife, 2023
Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. However, the high sequence and structural conservation of the catalytic kinase domain complicate the ...
Ian R Outhwaite, Sukrit Singh, Benedict-Tilman Berger, Stefan Knapp, John D Chodera, Markus A Seeliger   +5 more
doaj   +1 more source

Role of protein kinase C in renal vasoconstriction caused by angiotensin II [PDF]

, 1990
In this study we have examined the subcellar pathways along which angiotensin II (ANG II) causes renal vasoconstriction. Using the isolated perfused rat kidney model, we found that renal vasoconstriction produced by ANG II (100 pM) was not altered by the
Kurtz, Armin, Scholz, H., A. Kurtz, H. Scholz   +3 more
core   +1 more source

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2011
The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing ...
Roberta Bitencourt, Ilana Zalcberg, Iúri Drumond Louro   +2 more
doaj   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Technology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM, Yi Hou PhD, Liang-Chen Qi MD   +2 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis [PDF]

, 2012
Sphingosine kinases (SK) catalyze the phosphorylation of proapoptotic sphingosine to the prosurvival factor sphingosine 1-phosphate (S1P), thereby promoting oncogenic processes.
Zangemeister-Wittke, Uwe, Fabbro, Doriano, Doriano Fabbro, Huwiler Andrea, Zangemeister-Wittke Uwe, Huwiler, Andrea, Uwe Zangemeister-Wittke, Kotelevets Nataliya, Nataliya Kotelevets (156133), Kotelevets, Nataliya, Nataliya Kotelevets, Andrea Huwiler, Doriano Fabbro (156139), Andrea Huwiler (156145), Uwe Zangemeister-Wittke (156150), Fabbro Doriano   +15 more
core   +2 more sources

The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine. [PDF]

, 2011
Pharmacokinetics, pharmacodynamics and pharmacogenetics play an important role in drug discovery and contribute to treatment success. This is an essential issue in cancer treatment due to its high toxicity. During the last decade, cyclin-dependent kinase
Hassan, Moustapha, Sallam, Hatem, Hassan, Zuzana   +2 more
core   +4 more sources